← Back to Search

Topical Agent

ARQ-151 cream 0.3% for Psoriasis

Phase 2
Waitlist Available
Research Sponsored by Arcutis Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

Study Summary

This study is evaluating whether a cream containing a drug called ARQ-151 may help treat plaque psoriasis in children.

Eligible Conditions
  • Plaque Psoriasis
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Incidence of application site reactions
Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite

Side effects data

From 2022 Phase 2 trial • 20 Patients • NCT04655313
5%
Headache
5%
Candida infection
5%
Perineal erythema
5%
Perineal pain
5%
Back pain
5%
Application site pain
5%
Nasal congestion
5%
Dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
ARQ-151 Cream 0.3%

Trial Design

1Treatment groups
Experimental Treatment
Group I: ARQ-151 cream 0.3%Experimental Treatment1 Intervention
Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARQ-151 cream 0.3%
2021
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Arcutis Biotherapeutics, Inc.Lead Sponsor
21 Previous Clinical Trials
7,631 Total Patients Enrolled
10 Trials studying Psoriasis
2,750 Patients Enrolled for Psoriasis
David Berk, MDStudy DirectorArcutis Biotherapeutics, Inc.
21 Previous Clinical Trials
8,625 Total Patients Enrolled
8 Trials studying Psoriasis
2,220 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
2021. "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04746911.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top